Cautious. DSGN lacks the growth or profitability signals of a compounder (26/100 Value score), and while leadership shows moderate alignment through founder involvement, the vulnerability index at 100 signals structural or competitive headwinds that haven't been fully characterized. Requires clarity on moat durability before conviction.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Design Therapeutics, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 45/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Design Therapeutics, Inc. (DSGN) at 45/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. DSGN lacks the growth or profitability signals of a compounder (26/100 Value score), and while leadership shows moderate alignment through founder involvement, the vulnerability index at 100 signals structural or competitive headw
DSGN's current Stocky Verdict is 45/100, placing it in the "Cautious" band. This composite combines a 26/100 Compounder score, 62/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Design Therapeutics, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Design Therapeutics, Inc. scores 62/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Design Therapeutics, Inc.'s Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Design Therapeutics, Inc..
Sign up free and unlock the full analysis on DSGN — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for DSGN in the app.
